Clinical Trial Update: Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CSJ117 for symptom relief, pharmacodynamics, and safety in patients with chronic obstructive pulmonary disease (COPD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CSJ117

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED